How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

24 results for

Intraocular Parasympathomimetic

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Intraocular Parasympathomimetic

Intraocular Parasympathomimetic Intraocular Parasympathomimetic Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Intraocular (...) Parasympathomimetic Intraocular Parasympathomimetic Aka: Intraocular Parasympathomimetic , Intraocular Cholinergic , Ocular Parasympathomimetic Agent , Miotic , Intraocular Pilocarpine , Isoptocarpine , Pilopine gel , Ocusert , Carbachol , Echothiophate , Phospholine Iodide , Isopto Carbachol , Pilocar II. Indication second line agent (adjunctive) III. Mechanism Reduces resistance to aqueous outflow IV. Preparations (Isoptocarpine, Pilopine gel, Ocusert, Pilocar) 1 drop four times daily Carbachol (Isopto

2018 FP Notebook

2. Intraocular Parasympathomimetic

Intraocular Parasympathomimetic Intraocular Parasympathomimetic Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Intraocular (...) Parasympathomimetic Intraocular Parasympathomimetic Aka: Intraocular Parasympathomimetic , Intraocular Cholinergic , Ocular Parasympathomimetic Agent , Miotic , Intraocular Pilocarpine , Isoptocarpine , Pilopine gel , Ocusert , Carbachol , Echothiophate , Phospholine Iodide , Isopto Carbachol , Pilocar II. Indication second line agent (adjunctive) III. Mechanism Reduces resistance to aqueous outflow IV. Preparations (Isoptocarpine, Pilopine gel, Ocusert, Pilocar) 1 drop four times daily Carbachol (Isopto

2015 FP Notebook

3. Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade

Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2014 Clinical Trials

4. The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy

The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been

2014 Clinical Trials

5. Latanoprost

-angle glaucoma aim to prevent vision loss through lowering of intraocular pressure, but to our knowledge no placebo (...) -controlled trials have assessed visual function preservation, and the observation periods of previous (unmasked) trials have typically been at least 5 years. We assessed vision preservation in patients given latanoprost compared with those given placebo. In this randomised, triple-masked, placebo-controlled trial, we enrolled patients with newly diagnosed open-angle glaucoma (...) and reduction of severity of alopecia tool score of scalp and beard before and after treatment for all therapeutic groups. CONCLUSION 2017 5. Comparison of the Effects of Dorzolamide/Timolol Fixed Combination versus Latanoprost on Intraocular Pressure and Ocular Perfusion Pressure in Patients with Normal-Tension Glaucoma: A Randomized, Crossover Clinical Trial. 26756747 2016 01 13 2016 07 04 2017 02 20 1932-6203 11 1 2016 PloS one PLoS ONE Comparison of the Effects of Dorzolamide/Timolol Fixed Combination

2018 Trip Latest and Greatest

6. Incontinence - urinary, in women

[ ; ; ]. Urgency incontinence is idiopathic in most women [ ]. In some cases, it can be associated with systemic neurological conditions such as Parkinson's disease, multiple sclerosis, or injury to pelvic or spinal nerves [ ]. Comorbidities such as obesity, type 2 diabetes, and chronic urinary tract infection can increase urgency symptoms [ ]. In addition, the adverse effects of some drugs may also cause detrusor overactivity, such as parasympathomimetics, antidepressants, and hormone replacement

2017 NICE Clinical Knowledge Summaries

7. Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study. (PubMed)

with depression, respectively anxiety as dependent variable and self-reported glaucoma as independent variable were conducted and adjusted for socio-demographic factors, systemic comorbidities (arterial hypertension, myocardial infarction, stroke, diabetes mellitus, chronic obstructive pulmonary disease, cancer), ocular diseases (cataract, macular degeneration, corneal diseases, diabetic retinopathy), visual acuity, intraocular pressure, antiglaucoma eye drops (sympathomimetics, parasympathomimetics, carbonic

Full Text available with Trip Pro

2018 BMC Ophthalmology

8. Pulmonary safety of ophthalmic beta-blockers: a nationwide registry-based cohort study. (PubMed)

Pulmonary safety of ophthalmic beta-blockers: a nationwide registry-based cohort study. Ophthalmic beta-blockers, used in the treatment of increased intraocular pressure, are known to cause pulmonary adverse effects. Few, if any, studies have quantified the extent of the problem in a real-life population. In this nationwide study, we assess the pulmonary safety of patients initiating treatment with ophthalmic beta-blockers.Using the Danish Nationwide Registries from 1995 to 2012, we identified (...) all individuals aged 20-90 years who initiated monotherapy with an intraocular pressure-lowering drug, with or without concomitant obstructive pulmonary disease. Risks of (i) switching to another drug and (ii) new onset of obstructive pulmonary disease during a 90-day follow-up were examined by cumulative risk and logistic regression models adjusted for available covariates.The cohort consisted of 97 463 individuals. Odds ratios for drug switch in individuals without concomitant obstructive

2018 Acta ophthalmologica

9. Effect of Single Instillation of Three Different Topical Lubricants on Tear Film Thickness in Patients With Dry Eye Syndrome

] Schirmer I test measured at screening visit and on study Ocular Surface Disease Index (OSDI) score [ Time Frame: 1 day ] Ocular Surface Disease Index (OSDI) score assessed with questionnaire at screening visit Corneal fluorescein staining [ Time Frame: 2 weeks ] Corneal fluorescein staining at screening visit and on study day Visual acuity [ Time Frame: 2 weeks ] Visual acuity assessed at screening visit and on study day Intraocular pressure (IOP) [ Time Frame: 1 day ] Intraocular pressure measured (...) as judged by the clinical investigator Intake of parasympathomimetic or anti-psychotic drugs Wearing of contact lenses Glaucoma in the medical history Treatment with corticosteroids in the 4 weeks preceding the study Topical treatment with any ophthalmic drug except topical lubricants in the 4 weeks preceding the study Ocular infection or clinically significant inflammation not related to dry eye syndrome Ocular surgery in the 3 months preceding the study Sjögren's syndrome Stevens-Johnson syndrome

2017 Clinical Trials

10. Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

. Study subject primary endpoint evaluation will be assessed after 2 weeks (14 days) and 6 weeks (42 days) of treatment for each study subject deemed eligible for evaluation, (i.e., at Visit III - Day 14 ± 2 days and Visit IV - Day 42 ± 3 days). The primary bioequivalence comparison is between the test and reference products for the mean difference in intraocular pressure (IOP) of both eyes at four time points, i.e., at approximately 8:00 am and 10:00 am at the Day 14 (± 2 days) and Day 42 (± 3 days (...) to Primary Outcome Measures : mean difference in intraocular pressure (IOP) of both eyes between the two treatment groups at four time points [ Time Frame: day 42 ] The primary efficacy end point for this study will be the mean difference in intraocular pressure (IOP) of both eyes between the two treatment groups at four time points, i.e., at approximately 8:00 am (hour 0; before the morning drop) and 10:00 am (hour 2; after the morning drop) at the Day 14 (week 2) and Day 42 (week 6) visits Eligibility

2015 Clinical Trials

11. Glaucoma in pregnancy. (PubMed)

, the natural course of intraocular pressure during pregnancy, and a discussion of various therapeutic modalities during pregnancy and lactation.The risks of glaucoma medications during pregnancy are not well established for the human fetus or infant and are often inferred from animal studies. Some guidelines have been provided by the US Food and Drug Administration (FDA) about medication safety during pregnancy. Currently, brimonidine is classified as a category B medication with presumed safety based (...) on animal studies. Other glaucoma medications (beta blockers, carbonic anhydrase inhibitors, parasympathomimetics, and prostaglandin analogues) are classified as category C medications with uncertain safety from the lack of human studies and reported adverse effects in animal studies.The treatment of glaucoma during pregnancy and lactation requires careful consideration and understanding of disease status, stage of pregnancy, FDA classification and guidelines, and potential benefits and limitations

2014 Current Opinion in Ophthalmology

12. Scleral Expansion Procedure in Ocular Hypertension &amp (Treatment)

does a small linear increase in intraocular pressure occur with age in the normal population? This is shown in the image below. Intraocular pressure versus age in patients with normal intraocular pressure. Why does a parasympathomimetic medication, such as pilocarpine, produce a dramatic decrease in intraocular pressure in patients with ocular hypertension and POAG but only induce a minimal decrease in intraocular pressure in healthy patients? Increased aqueous inflow is not the cause of ocular (...) hypertension or POAG. Ocular hypertension and POAG are caused by a decrease in aqueous outflow. Aqueous outflow is controlled predominantly by trabecular meshwork pore size. Davanger examined the relationship of pore size to intraocular pressure using a hydrodynamic model. [ ] He found that as pore size decreases, intraocular pressure increases according to a hyperbolic function, as shown in the image below. Relationship of intraocular pressure to trabecular meshwork pore size. Because the crystalline lens

2014 eMedicine.com

13. Scleral Expansion Procedure in Ocular Hypertension &amp (Overview)

does a small linear increase in intraocular pressure occur with age in the normal population? This is shown in the image below. Intraocular pressure versus age in patients with normal intraocular pressure. Why does a parasympathomimetic medication, such as pilocarpine, produce a dramatic decrease in intraocular pressure in patients with ocular hypertension and POAG but only induce a minimal decrease in intraocular pressure in healthy patients? Increased aqueous inflow is not the cause of ocular (...) hypertension or POAG. Ocular hypertension and POAG are caused by a decrease in aqueous outflow. Aqueous outflow is controlled predominantly by trabecular meshwork pore size. Davanger examined the relationship of pore size to intraocular pressure using a hydrodynamic model. [ ] He found that as pore size decreases, intraocular pressure increases according to a hyperbolic function, as shown in the image below. Relationship of intraocular pressure to trabecular meshwork pore size. Because the crystalline lens

2014 eMedicine.com

14. Choroidal Detachment (Treatment)

drugs can be used. Osmotics and aqueous suppressants are recommended. Parasympathomimetics are contraindicated. Next: Surgical Care If choroidal detachment persists longer than 1 week after the underlying cause has been identified and addressed, drainage of the suprachoroidal fluid should be considered. The 7-day limit is an indication only; individualized assessment is key. If an improvement is suspected, waiting longer and closely monitoring the patient may be warranted. Immediate action (...) Disclosure: Received royalty and consulting fees for: Alcon Laboratories. Chief Editor Andrew A Dahl, MD, FACS Assistant Professor of Surgery (Ophthalmology), New York College of Medicine (NYCOM); Director of Residency Ophthalmology Training, The Institute for Family Health and Mid-Hudson Family Practice Residency Program; Staff Ophthalmologist, Telluride Medical Center Andrew A Dahl, MD, FACS is a member of the following medical societies: , , American Intraocular Lens Society, , , , , , Disclosure

2014 eMedicine.com

15. Glaucoma, Pigmentary (Treatment)

> Pigmentary Glaucoma Treatment & Management Updated: Oct 23, 2018 Author: Jim C Wang (王崇安), MD; Chief Editor: Hampton Roy, Sr, MD Share Email Print Feedback Close Sections Sections Pigmentary Glaucoma Treatment Approach Considerations The intraocular pressure (IOP) in pigment dispersion syndrome (PDS) and pigmentary glaucoma (PG) is subject to large spontaneous fluctuations. This tendency should be kept in mind when considering treatment and evaluating IOP response to therapies. Despite full PDS features (...) anhydrase inhibitors are useful agents for treating pigmentary glaucoma and are generally well tolerated. Systemic agents should be reserved for particularly difficult circumstances or when the risks of surgery are unacceptably high. Miotic therapy Parasympathomimetics may also be administered. Pupillary miosis increases resistance to aqueous flow from the posterior chamber, past the lens surface, and through the pupil into the anterior chamber. This increased resistance allows aqueous pressure to build

2014 eMedicine.com

16. Scleral Expansion Procedure in Ocular Hypertension &amp (Follow-up)

does a small linear increase in intraocular pressure occur with age in the normal population? This is shown in the image below. Intraocular pressure versus age in patients with normal intraocular pressure. Why does a parasympathomimetic medication, such as pilocarpine, produce a dramatic decrease in intraocular pressure in patients with ocular hypertension and POAG but only induce a minimal decrease in intraocular pressure in healthy patients? Increased aqueous inflow is not the cause of ocular (...) hypertension or POAG. Ocular hypertension and POAG are caused by a decrease in aqueous outflow. Aqueous outflow is controlled predominantly by trabecular meshwork pore size. Davanger examined the relationship of pore size to intraocular pressure using a hydrodynamic model. [ ] He found that as pore size decreases, intraocular pressure increases according to a hyperbolic function, as shown in the image below. Relationship of intraocular pressure to trabecular meshwork pore size. Because the crystalline lens

2014 eMedicine.com

17. Glaucoma, Pigmentary (Follow-up)

> Pigmentary Glaucoma Treatment & Management Updated: Oct 23, 2018 Author: Jim C Wang (王崇安), MD; Chief Editor: Hampton Roy, Sr, MD Share Email Print Feedback Close Sections Sections Pigmentary Glaucoma Treatment Approach Considerations The intraocular pressure (IOP) in pigment dispersion syndrome (PDS) and pigmentary glaucoma (PG) is subject to large spontaneous fluctuations. This tendency should be kept in mind when considering treatment and evaluating IOP response to therapies. Despite full PDS features (...) anhydrase inhibitors are useful agents for treating pigmentary glaucoma and are generally well tolerated. Systemic agents should be reserved for particularly difficult circumstances or when the risks of surgery are unacceptably high. Miotic therapy Parasympathomimetics may also be administered. Pupillary miosis increases resistance to aqueous flow from the posterior chamber, past the lens surface, and through the pupil into the anterior chamber. This increased resistance allows aqueous pressure to build

2014 eMedicine.com

18. Scleral Expansion Procedure in Ocular Hypertension &amp (Diagnosis)

does a small linear increase in intraocular pressure occur with age in the normal population? This is shown in the image below. Intraocular pressure versus age in patients with normal intraocular pressure. Why does a parasympathomimetic medication, such as pilocarpine, produce a dramatic decrease in intraocular pressure in patients with ocular hypertension and POAG but only induce a minimal decrease in intraocular pressure in healthy patients? Increased aqueous inflow is not the cause of ocular (...) hypertension or POAG. Ocular hypertension and POAG are caused by a decrease in aqueous outflow. Aqueous outflow is controlled predominantly by trabecular meshwork pore size. Davanger examined the relationship of pore size to intraocular pressure using a hydrodynamic model. [ ] He found that as pore size decreases, intraocular pressure increases according to a hyperbolic function, as shown in the image below. Relationship of intraocular pressure to trabecular meshwork pore size. Because the crystalline lens

2014 eMedicine.com

19. Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome

[ Time Frame: change from screening to after the last OCT measurement ] Total time frame is 14 days. Intraocular Pressure [ Time Frame: change from screening to after the last OCT measurement ] Total time frame is 14 days Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor (...) (Ocular Surface Disease Index) ≤ 32 and ≥ 13 Normal ophthalmic findings except dry eye syndrome, ametropia < 6 Dpt. No administration of topical lubricants 24 hours before the screening examination Exclusion Criteria: Participation in a clinical trial in the 3 weeks preceding the study Symptoms of a clinically relevant illness in the 3 weeks before the first study day Presence or history of a severe medical condition as judged by the clinical investigator Intake of parasympathomimetic or anti

2013 Clinical Trials

20. Double-blind cross-over comparison of aceclidine and pilocarpine in open-angle glaucoma. (PubMed)

Pilocarpine IM Aqueous Humor drug effects Clinical Trials as Topic Female Glaucoma drug therapy Humans Intraocular Pressure drug effects Male Miotics therapeutic use Parasympathomimetics therapeutic use Pilocarpine adverse effects therapeutic use Placebos Quinuclidines adverse effects therapeutic use Tonometry, Ocular 1970 8 1 1970 8 1 0 1 1970 8 1 0 0 ppublish 4917903 PMC1207904 Arch Ophthalmol. 1966 May;75(5):665-73 4956880 Am J Ophthalmol. 1967 Sep;64(3):405-15 6036300 Ann Ocul (Paris). 1967 Mar;200(3 (...) Double-blind cross-over comparison of aceclidine and pilocarpine in open-angle glaucoma. 4917903 1970 11 05 2018 11 13 0007-1161 54 8 1970 Aug The British journal of ophthalmology Br J Ophthalmol Double-blind cross-over comparison of aceclidine and pilocarpine in open-angle glaucoma. 510-21 Romano J H JH eng Clinical Trial Comparative Study Controlled Clinical Trial Journal Article England Br J Ophthalmol 0421041 0007-1161 0 Miotics 0 Parasympathomimetics 0 Placebos 0 Quinuclidines 01MI4Q9DI3

Full Text available with Trip Pro

1970 The British journal of ophthalmology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>